Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with haematological malignancies such as~  * any acute myeloid leukemia (AML) beyond Complete Remission (CR) 1~ * any acute lymphoblastic leukemia (ALL) beyond CR1~ * multiple myeloma (MM) at any relapse/progression, except refractory disease~ * MM with unfavourable cytogenetic profile at diagnosis~ * MM with less than a partial response (PR) after induction therapy~* Karnofsky Index ≥ 80 %~* Adequate contraception in female patients of child-bearing potential.~* Written informed consent~* Availability of one of the following:~  * A matched related or unrelated donor (MRD or MUD)~Exclusion Criteria:~* A hematopoietic cell transplantation-specific comorbidity index \> 4~* Active non-controlled infectious disease at the moment of inclusion~* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection~* Impaired liver function (Bilirubin \> 2.0 x upper normal limit; Transaminases \> 3.0 x upper normal limit)~* Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~* Pleural effusion or ascites \> 1.0 L~* Pregnancy or lactation~* Known hypersensitivity to treosulfan and/or fludarabine and/or rapamycin~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent~* Previous spinal cord radiotherapy with dose ≥ 45 Gy equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Treatment (Type: EXPERIMENTAL): Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;

Based on this trial design, predict the completion outcome and termination type (if applicable).